FENC Stock Price, Fennec Pharmaceuticals Quote, Chart

Market Summary

USD9.20+0.04

Market Closed

0.44%

FENC Alerts

3 major insider sales recently.

FENC Stock Price

View Fullscreen

FENC RSI Chart

FENC Valuation

Market Cap

249.3M

Price/Earnings (Trailing)

-9.05

Price/Sales (Trailing)

11.73

Price/Free Cashflow

-14.54

FENC Price/Sales (Trailing)

FENC Profitability

Return on Equity

236.97%

Return on Assets

-102.52%

Free Cashflow Yield

-6.88%

FENC Fundamentals

FENC Revenue

Revenue (TTM)

21.3M

Rev. Growth (Yr)

566.71%

Rev. Growth (Qtr)

58.1%

FENC Earnings

Earnings (TTM)

-27.5M

Earnings Growth (Yr)

-147.37%

Earnings Growth (Qtr)

-1.9K%

Breaking Down FENC Revenue

Last 7 days

-1.5%

Last 30 days

-17.0%

Last 90 days

-7.1%

Trailing 12 Months

7.7%

How does FENC drawdown profile look like?

FENC Financial Health

Current Ratio

3.56

Debt/Equity

-2.15

Debt/Cashflow

-0.69

FENC Investor Care

Shares Dilution (1Y)

2.61%

Diluted EPS (TTM)

-0.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	8.1M	14.7M	21.3M
2022	0	161.0K	59.0K	1.5M
2021	0	0	230.0K	174.0K
2020	0	0	271.0K	287.0K
2019	355.0K	392.0K	361.0K	315.0K
2018	103.0K	171.0K	256.0K	348.0K
2017	11.0K	13.0K	26.0K	47.0K
2016	0	5.0K	7.0K	8.0K
2015	5.0K	3.0K	4.0K	3.0K
2014	0	2.0K	2.0K	2.0K
2013	20.5K	0	11.3K	2.0K
2012	44.5K	46.0K	30.0K	26.5K
2011	0	0	0	43.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Fennec Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 22, 2024	haigh adrian	acquired	51,335	2.31	22,223	chief operating officer
Apr 22, 2024	haigh adrian	sold	-207,029	9.316	-22,223	chief operating officer
Apr 19, 2024	haigh adrian	acquired	51,332	2.31	22,222	chief operating officer
Apr 19, 2024	haigh adrian	sold	-207,442	9.335	-22,222	chief operating officer
Apr 18, 2024	haigh adrian	sold	-213,776	9.62	-22,222	chief operating officer
Apr 18, 2024	haigh adrian	acquired	51,332	2.31	22,222	chief operating officer
Apr 17, 2024	haigh adrian	sold	-220,220	9.91	-22,222	chief operating officer
Apr 16, 2024	haigh adrian	sold	-228,389	10.2776	-22,222	chief operating officer
Apr 16, 2024	haigh adrian	acquired	51,332	2.31	22,222	chief operating officer
Apr 15, 2024	rallis chris a	acquired	14,515	10.45	1,389	-

Which funds bought or sold FENC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	EUDAIMONIA ADVISORS LLC	added	8.18	26,455	393,192	0.21%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	added	4.63	19,074	535,112	-%
Apr 24, 2024	Hartford Financial Management Inc.	added	0.95	269	531,514	0.11%
Apr 23, 2024	AMALGAMATED BANK	reduced	-66.67	-14,000	7,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	35,909	108,598	-%
Apr 15, 2024	Legato Capital Management LLC	new	-	635,186	635,186	0.08%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	976	976	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1,294	12,177,400	12,791,500	-%

Are Funds Buying or Selling FENC?

Are funds buying FENC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FENC

No. of Funds

FENC Alerts

3 major insider sales recently.

Unveiling Fennec Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	solas capital management, llc	5.2%	1,378,513	SC 13G
Feb 14, 2023	sonic gp llc	9.2%	2,407,357	SC 13G/A
Feb 14, 2022	sonic fund ii, l.p.	9.3%	-	SC 13G/A
Feb 11, 2022	avoro capital advisors llc	4.6%	1,200,000	SC 13G/A
Feb 16, 2021	sonic fund ii, l.p.	9.4%	-	SC 13G
Feb 12, 2021	avoro capital advisors llc	6.5%	1,670,000	SC 13G/A
Feb 12, 2021	southpoint capital advisors lp	15.8%	4,077,214	SC 13G/A
May 04, 2020	essetifin spa	16.2%	3,993,694	SC 13D/A

Recent SEC filings of Fennec Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	4/A	Insider Trading
Apr 26, 2024	4/A	Insider Trading
Apr 22, 2024	144	Notice of Insider Sale Intent
Apr 22, 2024	4	Insider Trading
Apr 19, 2024	144	Notice of Insider Sale Intent
Apr 18, 2024	144	Notice of Insider Sale Intent
Apr 18, 2024	4	Insider Trading
Apr 17, 2024	144	Notice of Insider Sale Intent
Apr 16, 2024	144	Notice of Insider Sale Intent
Apr 16, 2024	4	Insider Trading

Peers (Alternatives to Fennec Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.3B	2.4B	-8.70%	-12.49%	91.05	6.31	15.42%	18.43%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Fennec Pharmaceuticals Inc News

Latest updates

Fennec Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2020Q4	2020Q3	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2
Revenue	58.1%	9,954	6,296	3,895	1,493	24.00	9.00	13.00	13.00	126	22.00	69.00	70.00	110	66.00	115	101	73.00	59.00	23.00	16.00	5.00
Gross Profit	46.3%	9,050	6,184	3,177	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	159.8%	18,711	7,201	-7,843	12,593	7,899	-5,009	-	-	-	-	11,448	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	14.3%	3,868	3,384	2,340	-10,255	7,053	3,878	3,684	2,931	2,293	4,491	2,481	1,068	2,844	1,009	1,382	1,050	1,867	1,102	-	-	-
R&D Expenses	166.7%	32.00	12.00	8.00	117	846	1,131	523	1,242	1,223	1,368	1,172	795	1,969	1,671	1,723	1,798	798	689	-	-	-
Interest Expenses	12.7%	115	102	-	153	24.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-1949.7%	-16,962	917	-5,444	-6,857	-8,089	-5,072	-4,427	-4,185	-3,238	-6,200	-3,610	-1,809	-4,730	-2,626	-2,984	-2,749	-2,587	-1,568	-	-	-
Net Income Margin	8.8%	-1.30*	-1.42*	-3.26*	-15.45*	-16.71*	-17.16*	-35.33*	-70.25*	-63.10*	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-76.1%	-4,860	-2,760	-3,946	-6,802	-5,010	-3,390	-3,245	-2,958	-3,284	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	34.5%	27.00	20.00	19.00	22.00	27.00	30.00	16.00	19.00	22.00	26.00	28.00	28.00	31.00	34.00	39.00	10.00	14.00	16.00	18.00	21.00	23.00
Current Assets	35.0%	27.00	20.00	19.00	22.00	27.00	30.00	16.00	19.00	22.00	-	28.00	28.00	31.00	34.00	39.00	10.00	14.00	16.00	18.00	20.00	23.00
Cash Equivalents	7.0%	13.00	12.00	15.00	18.00	24.00	30.00	15.00	18.00	21.00	24.00	27.00	27.00	30.00	33.00	39.00	10.00	14.00	15.00	14.00	20.00	23.00
Liabilities	30.2%	38.00	30.00	29.00	29.00	30.00	28.00	7.00	7.00	7.00	7.00	6.00	4.00	2.00	2.00	2.00	2.00	2.00	-	-	-	2.00
Current Liabilities	93.0%	8.00	4.00	4.00	4.00	5.00	3.00	3.00	2.00	2.00	2.00	1.00	3.00	2.00	3.00	3.00	2.00	2.00	1.00	1.00	1.00	2.00
Long Term Debt	-	-	-	-	-	-	25.00	4.00	5.00	5.00	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	1.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	25.00	4.00	5.00	5.00	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-221.3%	-11.62	10.00	-	-	-2.57	3.00	9.00	13.00	16.00	19.00	22.00	25.00	29.00	31.00	36.00	8.00	12.00	15.00	16.00	19.00	21.00
Retained Earnings	-201.7%	-219	216	-214	-209	-203	-196	-188	-183	-179	-175	-170	-166	-162	-158	-152	-147	-144	-140	-138	-133	-131
Additional Paid-In Capital	1.4%	62.00	61.00	60.00	58.00	57.00	57.00	55.00	54.00	53.00	52.00	51.00	50.00	49.00	49.00	49.00	49.00	48.00	48.00	47.00	45.00	45.00
Shares Outstanding	1.5%	27.00	27.00	27.00	26.00	26.00	26.00	26.00	26.00	26.00	26.00	26.00	26.00	26.00	-	-	-	-	-	-	-	-
Float	-	-	-	138	-	-	-	98.00	-	-	-	98.00	-	-	-	116	-	-	-	46.00	-	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-76.1%	-4,860	-2,760	-3,946	-5,577	-6,802	-5,010	-3,390	-2,856	-3,245	-2,958	-4,426	-3,593	-3,284	-5,446	-3,116	-3,749	-1,590	-2,235	-2,756	-2,479	-2,930
Share Based Compensation	-0.9%	857	865	2,543	1,089	827	1,853	1,008	399	919	917	1,326	587	640	1,238	522	391	461	314	1,669	221	222
Cashflow From Financing	2750.7%	5,730	201	514	193	824	19,847	46.00	15.00	10.00	-	4,968	-	462	-117	31,944	-	-	-	-	-71.00	1,187

FENC Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Consolidated Statements of Operations
PEDMARK, product sales, net	$ 21,252	$ 1,535
Cost of products sold	(1,259)	(86)
Gross profit	19,993	1,449
Operating expenses:
Research and development	56	3,531
Selling and marketing	12,123	2,785
General and administrative	20,585	17,722
Total operating expenses	32,764	24,038
Loss from operations	(12,771)	(22,589)
Other (expense)/income
Unrealized foreign exchange gain/(loss)	5	(9)
Amortization expense	(287)	(149)
Unrealized loss on securities	(39)	(184)
Interest income	441	195
Interest expense	(3,394)	(978)
Total other expense	(3,274)	(1,125)
Net loss	$ (16,045)	$ (23,714)
Basic net loss per common share	$ (0.60)	$ (0.90)
Diluted net loss per common share	$ (0.60)	$ (0.90)
Weighted-average number of common shares outstanding basic	26,574	26,275
Weighted-average number of common shares outstanding diluted	26,574	26,275

FENC Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 13,269	$ 23,774
Accounts receivable, net	8,814	1,545
Prepaid expenses	2,575	770
Inventory	2,156	576
Other current assets	44	63
Total current assets	26,858	26,728
Non-current assets
Deferred issuance cost	816	809
Deferred issuance cost (amortization)	(810)	(598)
Total non-current assets	6	211
Total assets	26,864	26,939
Current liabilities:
Accounts payable	3,778	2,390
Accrued liabilities	3,754	2,219
Operating lease liability - current	21
Total current liabilities	7,553	4,609
Long term liabilities
Term loan	30,000	25,000
PIK interest	1,219	260
Debt discount	(288)	(361)
Operating lease liability - net of current portion	2
Total long term liabilities	30,933	24,899
Total liabilities	38,486	29,508
Stockholders' deficit:
Common stock, no par value; unlimited shares authorized; 27,027 shares issued and outstanding (2022 26,361)	144,307	142,591
Additional paid-in capital	62,073	56,797
Accumulated deficit	(219,245)	(203,200)
Accumulated other comprehensive income	1,243	1,243
Total stockholders' deficit	(11,622)	(2,569)
Total liabilities and stockholders' deficit	$ 26,864	$ 26,939

About Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

CEO	Mr. Rostislav Raykov
WEBSITE	fennecpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	36

Fennec Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Fennec Pharmaceuticals Inc? What does FENC stand for in stocks?

FENC is the stock ticker symbol of Fennec Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fennec Pharmaceuticals Inc (FENC)?

As of Fri Apr 26 2024, market cap of Fennec Pharmaceuticals Inc is 249.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FENC stock?

You can check FENC's fair value in chart for subscribers.

What is the fair value of FENC stock?

You can check FENC's fair value in chart for subscribers. The fair value of Fennec Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Fennec Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FENC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Fennec Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether FENC is over valued or under valued. Whether Fennec Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Fennec Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FENC.

What is Fennec Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, FENC's PE ratio (Price to Earnings) is -9.05 and Price to Sales (PS) ratio is 11.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FENC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Fennec Pharmaceuticals Inc's stock?

In the past 10 years, Fennec Pharmaceuticals Inc has provided 0.325 (multiply by 100 for percentage) rate of return.